Combination therapy | Monotherapy | |
---|---|---|
TNFi persistence, overall (n=497) | ||
Median (IQR), months | 32.4 (12.0–NA) | 30.8 (13.7–67.1) |
HR (95% CI) | 0.95 (0.70 to 1.29) | |
p Value | 0.73 | |
TNFi persistence, adalimumab (n=214) | ||
Median (IQR), months | 29.5 (12.4–NA) | 29.1 (11.9–47.1) |
HR (95% CI) | 0.88 (0.54 to 1.44) | |
p Value | 0.61 | |
TNFi persistence, etanercept (n=155) | ||
Median (IQR), months | 19.1 (8.4–42.0) | 47.3 (19.3–71.6) |
HR (95% CI) | 1.93 (1.15 to 3.25) | |
p Value | 0.01 | |
TNFi persistence, infliximab (n=110) | ||
Median (IQR), months | NA (22.0–NA) | 16.3 (13.6–58.9) |
HR (95% CI) | 0.46 (0.24 to 0.88) | |
p Value | 0.02 | |
Time to remission* (n=380) | ||
Median (IQR), months | 20.7 (7.4–58.5) | 25.1 (8.1–64.6) |
HR (95% CI) | 1.09 (0.82 to 1.46) | |
p Value | 0.56 | |
Time to loss of remission† (n=33) | ||
Median (IQR), months | 9.3 (7.0–20.7) | 12.0 (7.8–NA) |
HR (95% CI) | 1.52 (0.63 to 3.68) | |
p Value | 0.35 |
HR and p value relative to TNFi monotherapy.
*Patients with at least 90 days of initial therapy. TNFi, only biologic in both groups.
†Patients with at least 90 days of initial therapy and who had remission on the first therapy switch. TNFi, only biologic in both groups.
NA, not available; TNFi, tumour necrosis factor inhibitor.